Search
Vaccines Treatment Options in Canada
A collection of 103 research studies where Vaccines is the interventional treatment. These studies are located in the Canada . Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
13 - 24 of 103
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years
Completed
This is a randomized, observer blind and controlled study. Participants in low-dose and high-dose IM group will be randomized in a ratio of 2:1 to receive either the investigational product or the control. Participants in the IH group will receive either inhaled investigational product or saline in a ratio of 3:1. Enrollment will be in an ascending order of dosage groups. All participants will receive 2 doses in 4 months interval. Blood samples will be collected for immunogenicity evaluation ove... Read More
Gender:
ALL
Ages:
Between 50 years and 65 years
Trial Updated:
12/02/2024
Locations: Canadian Center for Vaccinology, Halifax, Not set
Conditions: Herpes Zoster
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
Recruiting
The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with immunocompromising conditions (PLIC).
The main questions it aims to answer are:
1. Is co-administration of seasonal inactivated influenza vaccine (IIV) with the most up-to-date recommended COVID-19 booster dose non-inferior in inducing a 1-month peak protective humoral response again... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: Research Institute of McGill University Health Centre, Montréal, Quebec +1 locations
Conditions: COVID 19, Influenza, Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus, Inflammatory Bowel Disease, Solid Organ Transplant Recipients, Immunocompromised Host, People Living With HIV
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants
Completed
Primary objectives:
* To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection).
* To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups 1-4)
* To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of 3 doses in infants (... Read More
Gender:
ALL
Ages:
Between 42 days and 15 months
Trial Updated:
11/07/2024
Locations: The Children's Clinic Of Jonesboro PA Site Number : 8400143, Jonesboro, Arkansas +56 locations
Conditions: Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation, Pertussis Immunisation, Hepatitis B Immunisation, Haemophilus Influenzae Type b Immunisation, Polio Immunisation, Measles Immunisation, Rubella Immunisation, Varicella Immunisation, Mumps Immunisation
Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine
Completed
The purpose of this study was to assess immunogenicity and safety of MenABCWY vaccine in healthy adolescents and adults aged 15 to 25 years previously vaccinated with MenACWY vaccine.
Gender:
ALL
Ages:
Between 15 years and 25 years
Trial Updated:
06/07/2024
Locations: GSK Investigational Site, Jonesboro, Arkansas +68 locations
Conditions: Meningitis, Meningococcal
Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer
Terminated
This study examines the safety and efficacy of using the Imvamune smallpox vaccine in the treatment of non-melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2024
Locations: McGill University Health Centre, Montréal, Quebec
Conditions: Non-melanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
Completed
This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid \[TT\]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine \[23-PPV\] either unboosted or boosted with 13-valent pneumococcal conjugate vaccine \[13-PCV\], influenza vaccine, keyhole limpet hemocyanin \[KLH\]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/29/2024
Locations: North Central Neurology Associates, Cullman, Alabama +21 locations
Conditions: Multiple Sclerosis, Relapsing-Remitting
Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults
Completed
The purpose of this study was to evaluate the effectiveness of 2 doses or 3 doses of GSK's licenced meningococcal group B Bexsero (rMenB+OMV NZ) vaccine and of 2 doses of GSK's investigational combined meningococcal (MenABCWY) vaccine (GSK3536819A) in healthy adolescents and young adults. The immunogenicity and safety were evaluated in the study.
Gender:
ALL
Ages:
Between 10 years and 25 years
Trial Updated:
02/09/2024
Locations: GSK Investigational Site, Chandler, Arizona +111 locations
Conditions: Infections, Meningococcal
V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)
Completed
This study evaluated the safety, tolerability, and efficacy of the cytomegalovirus (CMV) vaccine (V160) administered in a 2-dose or 3-dose regimen to healthy seronegative women 16 to 35 years of age. Participants received blinded V160 on Day 1, Month 2, and Month 6 (3-dose regimen), V160 on Day 1 and Month 6 and placebo at Month 2 (2-dose regimen), or placebo on Day 1, Month 2, and Month 6, and were followed to approximately Month 24. The primary hypothesis of the study was that administration o... Read More
Gender:
FEMALE
Ages:
Between 16 years and 35 years
Trial Updated:
01/19/2024
Locations: Alabama Clinical Therapeutics ( Site 0025), Birmingham, Alabama +94 locations
Conditions: Cytomegalovirus (CMV) Infections
Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
Completed
This Phase 3 study was intended to assess the relative efficacy of the Quadrivalent VLP Influenza Vaccine during the 2018-2019 influenza season compared to a licensed vaccine in elderly adults 65 years of age and older. One dose of VLP Influenza Vaccine (30 μg/strain) or of Comparator (15 μg/strain) was to be administered to 12,738 participants.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
05/29/2023
Locations: (Site 225) Coastal Clinical Research, Mobile, Alabama +103 locations
Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
Completed
This study is designed to evaluate the safety and tolerability of 20vPnC in healthy infants.
Gender:
ALL
Ages:
Between 42 days and 98 days
Trial Updated:
05/18/2023
Locations: Eclipse Clinical Research, Tucson, Arizona +96 locations
Conditions: Pneumococcal Disease
Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.
Completed
Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to \<72 Months of Age. The study was conducted during the 2013/2014 and 2014/2015 northern hemisphere influenza season.
Gender:
ALL
Ages:
Between 6 months and 71 months
Trial Updated:
03/22/2023
Locations: 222, Novartis Investigational Site, Chandler, Arizona +166 locations
Conditions: Influenza Virus
SafeTy and Efficacy of Preventative CoVID Vaccines
Unknown
The STOPCoV study is a decentralized study comparing COVID-19 vaccine specific antibody levels at 24 weeks after final vaccine dose. We plan to study the safety and immunogenicity of COVID-19 vaccine(s) in community dwelling persons 70 years and over relative to a younger group (aged 30 - 50 years).
Gender:
ALL
Ages:
30 years and above
Trial Updated:
01/03/2023
Locations: University Health Network, Toronto, Ontario
Conditions: COVID-19 Virus Infection, Vaccine Response
13 - 24 of 103